Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Goodwill & Intangibles (2018 - 2026)

Akebia Therapeutics has reported Goodwill & Intangibles over the past 8 years, most recently at $59.0 million for Q4 2025.

  • Quarterly Goodwill & Intangibles changed 0.07% to $59.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $59.0 million through Dec 2025, changed 0.07% year-over-year, with the annual reading at $59.0 million for FY2025, 0.07% changed from the prior year.
  • Goodwill & Intangibles was $59.0 million for Q4 2025 at Akebia Therapeutics, roughly flat from $59.0 million in the prior quarter.
  • Over five years, Goodwill & Intangibles peaked at $190.2 million in Q1 2021 and troughed at $59.0 million in Q4 2024.
  • The 5-year median for Goodwill & Intangibles is $108.6 million (2023), against an average of $112.5 million.
  • Year-over-year, Goodwill & Intangibles tumbled 43.58% in 2021 and then increased 0.07% in 2025.
  • A 5-year view of Goodwill & Intangibles shows it stood at $167.1 million in 2021, then dropped by 21.57% to $131.1 million in 2022, then decreased by 27.46% to $95.1 million in 2023, then tumbled by 37.95% to $59.0 million in 2024, then rose by 0.07% to $59.0 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Goodwill & Intangibles are $59.0 million (Q4 2025), $59.0 million (Q3 2025), and $59.0 million (Q2 2025).